Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

DE (n=1) and 12 percent of

patients receiving adefovir (n=5) experienced a serious adverse event.

-- No deaths were observed in either treatment group.

-- No patients in the BARACLUDE arm and one patient in the adefovir arm

experienced an ALT flare (defined as ALT greater than two times

baseline and greater than 10 times the upper limit of normal).

About the Study

The E.A.R.L.Y. study (ETV-079) is a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating antiviral activity as measured by mean reduction in viral load, or levels of hepatitis B virus (HBV DNA) in the blood. HBeAg or e-antigen, is a viral protein associated with hepatitis B infections, and is found in the blood only when there is virus present.

The primary endpoint for the study was mean reduction in HBV DNA levels at week 12. The secondary endpoints included the mean change in viral load from baseline through week 96, the proportion of patients in each treatment group who achieved ALT normalization, HBeAg loss and HBe seroconversion, and safety.

Sixty-nine patients were randomized in the study and of these, 65 completed the first 12 weeks. Patients in this study received either 0.5 mg of BARACLUDE(R) (entecavir) once daily (n=33) or 10 mg of adefovir once daily (n=32) for a minimum of 52 weeks. Patients in the BARACLUDE treatment group had a mean baseline viral load of 10.26 log(10) copies/mL. Patients in the adefovir treatment group had a mean baseline viral load of 9.88 log(10) copies/mL.

According to study protocol, patients who achieved a treatment response at 52 weeks discontinued treatment and entered a follow-up monitoring phase. Three BARACLUDE-treated patients and four adefovir-treated patients met this criterion and entered the follow-up monitoring phase lasting up to 48 weeks. Patients who did not achieve a treatment response at 52 weeks continued on study
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader ... and partnership with RCA Medical, a subsidiary of Ascendis ... . Each year, hundreds of millions of ... infections as organisms are transmitted from patient to patient ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... , BETHESDA, Md. , ... CHDX ), a leading independent American provider of Western,healthcare products and ... the Company plans to release third quarter fiscal year 2010,financial results ... will host a conference call at 8:00 am ET ...
... , RICHMOND, Calif. , ... announced that the company will release its fourth quarter and full year ... market closes. The press release will be followed by a conference call ... public via telephone and webcast. During the conference call, the company will ...
Cached Medicine Technology:Chindex International to Report Third Quarter Fiscal Year 2010 Financial Results 2Chindex International to Report Third Quarter Fiscal Year 2010 Financial Results 3Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast 2
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Payday lending ... vulnerable communities and cause financial distress to the states ... analysts at Howard University’s Center on Race and Wealth. ... in economic activity, payday loans at the same time ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... Study Gives Floridians Access to Nursing Home, Assisted Living, Home ... Zip Code StatewideRICHMOND, Va., April 30 The ... a rate outpacing inflation, putting further financial pressure on those ... Genworth Financial. At the same time, the current economic ...
... /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug ... products that are delivered to and through the skin using ... financial and operational results for the quarter ended March 31, ... - Successfully completed all Pennsaid(R) studies necessary to ...
... PRINCETON, N.J., April 3 In conjunction with its first quarter ... April 29, 2009), Covance Inc. (NYSE: CVD ) is ... call that will be broadcast live over the Internet on Thursday, ... Covance First Quarter 2009 Earnings Webcast and Slide Presentation, ...
... UCLA neurosurgeons will be featured in a documentary for ... will put their skills to the test as they perform ... stepson.TAMPA, Fla., April 30 Two of UCLA,s ... Tumor Awareness Month. Dr. Linda Liau, Professor of neurosurgery and ...
... and book, "Dr. A,s Habits of Health" which is helping thousands ... ... April 30, 2009 -- Dr. Wayne Scott Andersen, a leading critical ... "Dr A,s Habits of Health" will present three free seminars in ...
... Insurance and Student Funding Group team up to ensure international students can ... ... San Jose, CA (PRWEB) April 30, 2009 -- With a rise in ... study, Go One Global (G1G Travel Insurance Services) Corp. has teamed up ...
Cached Medicine News:Health News:Growth in Florida Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Florida Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Florida Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Florida Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 5Health News:Nuvo announces 2009 first quarter financial results 2Health News:Nuvo announces 2009 first quarter financial results 3Health News:Nuvo announces 2009 first quarter financial results 4Health News:Nuvo announces 2009 first quarter financial results 5Health News:Nuvo announces 2009 first quarter financial results 6Health News:Nuvo announces 2009 first quarter financial results 7Health News:Nuvo announces 2009 first quarter financial results 8Health News:Nuvo announces 2009 first quarter financial results 9Health News:Nuvo announces 2009 first quarter financial results 10Health News:Nuvo announces 2009 first quarter financial results 11Health News:Two UCLA Neurosurgeons to Be Showcased in Documentary for the First Official National Brain Tumor Awareness Month 2Health News:Two UCLA Neurosurgeons to Be Showcased in Documentary for the First Official National Brain Tumor Awareness Month 3Health News:Physician and Author to Share Clinically Proven System for Permanent Weight Loss and Optimal Health in Westerville and Dublin, Ohio Areas 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 2Health News:New G1G Student Medical Insurance and Student Fee Protection Now on StuFund Web Site 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: